181 related articles for article (PubMed ID: 36009907)
1. Identification of Novel Inhibitor of Enoyl-Acyl Carrier Protein Reductase (InhA) Enzyme in
Singh K; Pandey N; Ahmad F; Upadhyay TK; Islam MH; Alshammari N; Saeed M; Al-Keridis LA; Sharma R
Antibiotics (Basel); 2022 Aug; 11(8):. PubMed ID: 36009907
[No Abstract] [Full Text] [Related]
2. Docking studies on novel alkaloid tryptanthrin and its analogues against enoyl-acyl carrier protein reductase (InhA) of Mycobacterium tuberculosis.
Tripathi A; Wadia N; Bindal D; Jana T
Indian J Biochem Biophys; 2012 Dec; 49(6):435-41. PubMed ID: 23350278
[TBL] [Abstract][Full Text] [Related]
3. Elucidation of marine fungi derived anthraquinones as mycobacterial mycolic acid synthesis inhibitors: an in silico approach.
Sharma A; Islam MH; Fatima N; Upadhyay TK; Khan MKA; Dwivedi UN; Sharma R
Mol Biol Rep; 2019 Apr; 46(2):1715-1725. PubMed ID: 30715689
[TBL] [Abstract][Full Text] [Related]
4. Molecular docking studies on InhA, MabA and PanK enzymes from Mycobacterium tuberculosis of ellagic acid derivatives from Ludwigia adscendens and Trewia nudiflora.
Shilpi JA; Ali MT; Saha S; Hasan S; Gray AI; Seidel V
In Silico Pharmacol; 2015 Dec; 3(1):10. PubMed ID: 26820895
[TBL] [Abstract][Full Text] [Related]
5. Structure-Based Design and in Silico Screening of Virtual Combinatorial Library of Benzamides Inhibiting 2-trans Enoyl-Acyl Carrier Protein Reductase of
Kouman KC; Keita M; Kre N'Guessan R; Owono Owono LC; Megnassan E; Frecer V; Miertus S
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554227
[TBL] [Abstract][Full Text] [Related]
6. Novel Hybrid 1,2,4- and 1,2,3-Triazoles Targeting Mycobacterium Tuberculosis Enoyl Acyl Carrier Protein Reductase (InhA): Design, Synthesis, and Molecular Docking.
El Sawy MA; Elshatanofy MM; El Kilany Y; Kandeel K; Elwakil BH; Hagar M; Aouad MR; Albelwi FF; Rezki N; Jaremko M; El Ashry ESH
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563096
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
Doğan ŞD; Gündüz MG; Doğan H; Krishna VS; Lherbet C; Sriram D
Eur J Med Chem; 2020 Aug; 199():112402. PubMed ID: 32417538
[TBL] [Abstract][Full Text] [Related]
8. Discovery of New and Potent InhA Inhibitors as Antituberculosis Agents: Structure-Based Virtual Screening Validated by Biological Assays and X-ray Crystallography.
Kamsri P; Hanwarinroj C; Phusi N; Pornprom T; Chayajarus K; Punkvang A; Suttipanta N; Srimanote P; Suttisintong K; Songsiriritthigul C; Saparpakorn P; Hannongbua S; Rattanabunyong S; Seetaha S; Choowongkomon K; Sureram S; Kittakoop P; Hongmanee P; Santanirand P; Chen Z; Zhu W; Blood RA; Takebayashi Y; Hinchliffe P; Mulholland AJ; Spencer J; Pungpo P
J Chem Inf Model; 2020 Jan; 60(1):226-234. PubMed ID: 31820972
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides.
He X; Alian A; Ortiz de Montellano PR
Bioorg Med Chem; 2007 Nov; 15(21):6649-58. PubMed ID: 17723305
[TBL] [Abstract][Full Text] [Related]
10. 4-Aryl-1,4-Dihydropyridines as Potential Enoyl-Acyl Carrier Protein Reductase Inhibitors: Antitubercular Activity and Molecular Docking Study.
Venugopala KN; Deb PK; Pillay M; Chopra D; Chandrashekharappa S; Morsy MA; Aldhubiab BE; Attimarad M; Nair AB; Sreeharsha N; Kandeel M; Venugopala R; Mohanlall V
Curr Top Med Chem; 2021; 21(4):295-306. PubMed ID: 33138763
[TBL] [Abstract][Full Text] [Related]
11. Multiple receptor conformers based molecular docking study of fluorine enhanced ethionamide with mycobacterium enoyl ACP reductase (InhA).
Khan AM; Shawon J; Halim MA
J Mol Graph Model; 2017 Oct; 77():386-398. PubMed ID: 28957755
[TBL] [Abstract][Full Text] [Related]
12. Mycobacterium enoyl acyl carrier protein reductase (InhA): A key target for antitubercular drug discovery.
Prasad MS; Bhole RP; Khedekar PB; Chikhale RV
Bioorg Chem; 2021 Oct; 115():105242. PubMed ID: 34392175
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid.
Parikh SL; Xiao G; Tonge PJ
Biochemistry; 2000 Jul; 39(26):7645-50. PubMed ID: 10869170
[TBL] [Abstract][Full Text] [Related]
14. Identification of some novel pyrazolo[1,5-a]pyrimidine derivatives as InhA inhibitors through pharmacophore-based virtual screening and molecular docking.
Modi P; Patel S; Chhabria MT
J Biomol Struct Dyn; 2019 Apr; 37(7):1736-1749. PubMed ID: 29663870
[TBL] [Abstract][Full Text] [Related]
15. Development of 1,2,4-Triazole-5-Thione Derivatives as Potential Inhibitors of Enoyl Acyl Carrier Protein Reductase (InhA) in Tuberculosis.
Vora D; Upadhyay N; Tilekar K; Jain V; Ramaa CS
Iran J Pharm Res; 2019; 18(4):1742-1758. PubMed ID: 32184843
[TBL] [Abstract][Full Text] [Related]
16. A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis.
Luckner SR; Liu N; am Ende CW; Tonge PJ; Kisker C
J Biol Chem; 2010 May; 285(19):14330-7. PubMed ID: 20200152
[TBL] [Abstract][Full Text] [Related]
17. Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data.
Kuo MR; Morbidoni HR; Alland D; Sneddon SF; Gourlie BB; Staveski MM; Leonard M; Gregory JS; Janjigian AD; Yee C; Musser JM; Kreiswirth B; Iwamoto H; Perozzo R; Jacobs WR; Sacchettini JC; Fidock DA
J Biol Chem; 2003 Jun; 278(23):20851-9. PubMed ID: 12606558
[TBL] [Abstract][Full Text] [Related]
18. Tryptanthrin Analogues as Inhibitors of Enoyl-acyl Carrier Protein Reductase: Activity against Mycobacterium tuberculosis, Toxicity, Modeling of Enzyme Binding.
Duca G; Pogrebnoi S; Boldescu V; Aksakal F; Uncu A; Valica V; Uncu L; Negres S; Nicolescu F; Macaev F
Curr Top Med Chem; 2019; 19(8):609-619. PubMed ID: 30834838
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel InhA reductase inhibitors: application of pharmacophore- and shape-based screening approach.
Kumar UC; Bvs SK; Mahmood S; D S; Kumar-Sahu P; Pulakanam S; Ballell L; Alvarez-Gomez D; Malik S; Jarp S
Future Med Chem; 2013 Mar; 5(3):249-59. PubMed ID: 23464516
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, Biological Evaluation and Molecular Docking Studies of New Pyrazolines as an Antitubercular and Cytotoxic Agents.
Lokesh BVS; Prasad YR; Shaik AB
Infect Disord Drug Targets; 2019; 19(3):310-321. PubMed ID: 30556506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
